SCHEMBL2294510

SCHEMBL2294510

O=C(O)CC(c1ccccc1)n1cnc2ccc(NC(=O)C34CC5CC(CC(C5)C3)C4)cc21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.42
NPSR1 Q6W5P4 2/20 0.42
TSHR P16473 1/20 0.42
CNR2 P34972 1/20 0.41
ALDH1A1 P00352 3/20 0.40
KDM4E B2RXH2 2/20 0.40
TP53 P04637 1/20 0.40
HPGD P15428 1/20 0.40
CA9 Q16790 2/20 0.40
ENPP3 O14638 1/20 0.40
CA2 P00918 1/20 0.40
ENPP1 P22413 1/20 0.40
ENPP2 Q13822 1/20 0.40
EPHX2 P34913 2/20 0.38
ALOX5 P09917 1/20 0.38
P2RX7 Q99572 1/20 0.38
CYP2D6 P10635 1/20 0.38
MAPT P10636 1/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2294620 0.93 SMN1; SMN2 (0.42) SMN1; SMN2NPSR1TSHRCNR2ALDH1A1
SCHEMBL5280528 0.81 NPSR1 (0.45) SMN1; SMN2NPSR1ALDH1A1KDM4ECYP2D6
SCHEMBL2292264 0.81 NPC1 (0.44) SMN1; SMN2ALDH1A1KDM4ETP53MAPT
SCHEMBL2292578 0.80 KDM4E (0.44) SMN1; SMN2NPSR1ALDH1A1KDM4ETP53
SCHEMBL2294478 0.80 NPC1 (0.48) SMN1; SMN2TP53MAPTMEN1KMT2A
SCHEMBL2294191 0.79 NPC1 (0.38) SMN1; SMN2NPSR1CYP2D6MAPTKMT2A
SCHEMBL2298596 0.79 SIRT2 (0.38) SMN1; SMN2ALDH1A1TP53HPGDMEN1
SCHEMBL2294482 0.79 NAMPT (0.48) SMN1; SMN2ALDH1A1KDM4EEPHX2MEN1
SCHEMBL5287131 0.78 L3MBTL1 (0.45) SMN1; SMN2NPSR1ALDH1A1KDM4ELMNA
SCHEMBL2299775 0.78 HTR1E (0.53) TSHRALDH1A1TP53CYP2D6MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8003806-B2 Integrin antagonists useful as anticancer agents OSI Pharmaceuticals, LLC (US) 2011-08-23 US claimed
EP-1828144-A2 INTEGRIN ANTAGONISTS USEFUL AS ANTICANCER AGENTS OSI Pharmaceuticals, Inc. (US) 2007-09-05 EP claimed
US-20060116383-A1 Integrin antagonists useful as anticancer agents ALCATEL LUCENT (FR) 2006-06-01 US claimed
WO-2006053342-A2 INTEGRIN ANTAGONISTS USEFUL AS ANTICANCER AGENTS OSI PHARMACEUTICALS, INC. (US) 2006-05-18 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060116383-A1 Integrin antagonists useful as anticancer agents ITGB5, ITGA5, ITGB1 SMN1; SMN2 2159/4885NPSR1 1814/4885TSHR 1897/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.